Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000054.xml
Download PDF
Pharmacopsychiatry 2018; 51(01/02): 5-6
DOI: 10.1055/s-0043-118103
DOI: 10.1055/s-0043-118103
Editorial
Editorial to Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology
Authors
Further Information
Publication History
received 31 July 2017
revised 02 August 2017
accepted 04 August 2017
Publication Date:
19 September 2017 (online)
-
References
- 1 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
- 2 De Leon J. A Critical Commentary on the 2017 AGNP Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry 2018; 51: 63-68
- 3 Baumann P, Hiemke C, Ulrich S. et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265
- 4 Hiemke C, Baumann P, Bergemann N. et al. AGNP Consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
- 5 Hicks JK, Bishop JR, Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for cyp2d6 and cyp2c19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98: 127-134
- 6 Gendiagnostik-Kommission. Richtlinie der Gendiagnostik-Kommission (GEKO) für die Beurteilung genetischer Eigenschaften hinsichtlich ihrer Bedeutung für die Wirkung eines Arzneimittels bei einer Behandlung gemäß § 23 Abs. 2 Nr. 1b GenDG. Bundesgesundheitsbl 2017; 60: 472-475 (Available from http://www.rki.de/DE/Content/Kommissionen/GendiagnostikKommission/Richtlinien/RL-WirkungArzneimittel.pdf?__blob=publicationFile [Accessed 07/31/2017])